Stay updated with breaking news from Current Clinical. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Randomized controlled trial meets primary endpoint and finds statistically significant durable patient benefit 3.4 years post-treatmentHOUSTON--(BUSINESS WIRE)--InGeneron, Inc., a clinical-stage biotechnology company, today announced positive clinical trial data demonstrating long-term safety and efficacy of InGener...
/PRNewswire/ -- The "IRT Benchmarking & Market Dynamics (4th Ed)" report has been added to ResearchAndMarkets.com's offering. The Interactive Response...
U.S. Food and Drug Administration Approves Two Opdivo® (nivolumab)-Based Regimens as First-Line Treatments for Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma - read this article along with other careers information, tips and advice on BioSpace
U.S. Food and Drug Administration Approves Two Opdivo® (nivolumab)-Based Regimens as First-Line Treatments for Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Milwaukee, WI (PRWEB) May 18, 2022 -- SITC's "Targets for Cancer IO: A Deep Dive Series" Offers In-Depth Presentations on Cancer ImmunotherapyMILWAUKEE –